Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Valeo Pharma Inc VPHIF

Valeo Pharma Inc. is a Canadian pharmaceutical company. The Company acquires, or in-licenses branded pharmaceuticals and hospital specialty products for sale in Canada. The Company is engaged in the commercialization of prescription products in Canada with a focus on respiratory/allergy, ophthalmology and hospital specialty products. Its respiratory/allergy products include Enerzair Breezhaler, Atectura Breezhaler and Allerject. The ophthalmology products include Xiidra and Simbrinza. Its specialty products include Redesca, Onstryv, M-Eslon, Yondelis and Ametop Gel 4%. The Company's wholly owned subsidiary is VPI Pharmaceuticals Inc.


GREY:VPHIF - Post by User

Post by Royal10on Dec 10, 2021 10:32am
243 Views
Post# 34218394

NFG: $25-million financing closed.

NFG: $25-million financing closed.VALEO PHARMA, a  strong growth and succesful pharmaceutical company based in Montreal (selling prescriptions
across Canada), has closed a big financing of convertible debentures of $25-million with INVESTISSEMENT QUEBEC. VPH expects to become profitable in Q4/21 after having announced a 280% revenue growth ($5.7-million)
in Q3. Very undervalued. Insiders bought 400,000 shares on December 1/21 and 640,000 rights  were granted on
Dec. 8/21. This is an undiscovered gem!
<< Previous
Bullboard Posts
Next >>